Flagship · Bulletin

Macro rationale

Neutral holds. Live inputs lean constructive (VIX 16.7, −10.6% vs 200d; HY OAS below 90d SMA; both indices above 200d), but the July 9 brief's confirmed complacency gap (NFCI −0.516, June NFP +57K with 74K downward revisions, markets pricing near-zero war premium against an active Hormuz shooting war, NAAIM 84.69) warrants the upper half of the NEUTRAL band. QQQ ~8% above 200d is one tick from the extension threshold. No cash-escalator signal fired; base band 5-15%, working reserve 14%. Regime is unchanged from last run — no escalator fired or cleared, so cash holds ~5% (band floor) rather than chasing the reserve; the four-day chip selloff is sentiment rotation (TSMC capex-raise repricing), not a durability break in any compute thesis. Energy/defense tilts remain validated by confirmed Hormuz escalation; compute/biology de-emphasized on valuation stretch and regulatory lag respectively.

Thesis

Scope-locked event-driven patch. The one binding action is the mandatory §2/§3 biology pillar-floor cure: biology sits at exactly 10.00% on entry-weight (LLY 4.86 + VRTX 2.23 + ARGX 2.91), triggering the auto-fire. I lift it over the floor to 12.00% by adding +2pp to VRTX — the highest-conviction (76), thesis-intact biology compounder (CF monopoly cash engine, $3.71B TTM FCF, $10B Crinetics acquisition diversifying beyond CF). I fund the add entirely from a −2pp trim of ASML (score 64, weakening toward the broken floor, EUV monopoly intact but the compute pillar is brief-de-emphasized on valuation stretch and the AI-load look-through is over its 45% cap) — so net cash is unchanged and the working reserve isn't drawn down. I decline all four optional biology opportunity opens: NVO is a decelerating franchise in re-entry cooldown with no new positive flow, and RGEN/ILMN/SDGR each carry red-team cautions (entry triggers unmet, stretched/eroding). Adding to a proven in-book name beats opening a flagged story stock. PSN remains broken (score 50) but out of scope — deferred again to the next full deep run where a replacement open is permitted. All other 16 names held verbatim at delta 0.

Reflection

Mandatory biology pillar-floor cure — biology at exactly 10.00% entry-weight; top up VRTX funded by trimming weakening ASML. No regime shift; chip selloff is sentiment rotation.

The biology floor keeps auto-firing because LLY's live drift (9.15%) masks a thin entry-weight base (4.86%); the durable fix is building the second/third legs (VRTX, ARGX), not opening flagged story stocks. I deliberately declined all four opportunity opens — NVO is a decelerating franchise in re-entry cooldown with no new positive flow, and RGEN/ILMN/SDGR each fail the durability bar (entry triggers unmet, stretched/eroding). Adding to a proven 76-score in-book compounder beats a caution-flagged new name. ASML at 64 is the cleanest compute funding source amid the TSMC-capex-driven rotation. P

Positions (18)

• MUMicron Technologycompute

  hold2.89%79
  flow steadyconf

  Funder

  US HBM3E/HBM4 supplier; 84.6% GM, FCF+. 16 Strategic Customer Agreements covering ~20% DRAM/~1/3 NAND through 2030 (~$100B contracted); ~$725B 2026 hyperscaler capex line + Anthropic multi-year supply agreement anchor demand.

  Unwind

  DRAM/NAND spot-price collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; SCA contract-book erosion.

  Catalyst

  FQ4 earnings + DRAM/NAND spot-pricing trend after the TSMC-capex-driven sector selloff

  Scenarios · 12mo targets

  $950.00 base

  $1,150.00 bull — HBM4 ramp + capacity-disciplined cycle keeps memory tight; SCA book converts to record FCF.

  $620.00 bear — Memory cycle rolls over, HBM oversupply, hyperscaler capex pause.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold6.55%83
  flow acceleratingconf

  Funder

  World-leading <=3nm foundry monopoly, >50% GM, prodigious FCF. Q2 rev +33%/EPS +77% YoY; $100B additional Arizona investment + CHIPS $6.6B disbursement; every meaningful AI accelerator (NVDA/AMD/AVGO custom silicon) routes through TSMC.

  Unwind

  Gross margin sustained <50% for two consecutive quarters.

  Catalyst

  Monthly sales + Q3 earnings; Arizona capex margin trajectory

  Scenarios · 12mo targets

  $460.00 base

  $560.00 bull — AI-capex supercycle + Arizona ramp lift leading-edge pricing and share.

  $310.00 bear — AI-capex digestion + Taiwan geopolitical premium compress the multiple.

• NVDANVIDIAcompute

  hold2.36%72
  flow steadyconf

  Funder

  AI accelerator monopoly + CUDA software moat, ~75% GM, fortress balance sheet. ~$725B 2026 hyperscaler capex on Blackwell/Rubin (MSFT/AMZN/GOOGL/META); Stargate $500B JV; trades ~24x fwd P/E vs AMD 75x.

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters.

  Catalyst

  Next data-center revenue print (two-quarter <20% YoY test)

  Scenarios · 12mo targets

  $240.00 base

  $300.00 bull — Rubin ramp + sovereign AI broaden demand; inference share holds.

  $150.00 bear — Custom-ASIC in-sourcing + export-control hit slow data-center growth.

• ASMLASML Holdingcompute

  trim1.36%-2.00pp64
  flow softeningconf

  Funder

  EUV/High-NA monopoly — only viable path to leading-edge logic, ~50% GM, multi-year backlog. Norway GPFG holds, Coatue/Third Point added Q1; TSMC/Samsung/Intel 2025-27 EUV orderbook backstops cash flow.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; EUV export-control tightening cuts the orderbook.

  Catalyst

  Next quarterly bookings / book-to-bill print

  Scenarios · 12mo targets

  $1,950.00 base

  $2,400.00 bull — High-NA orders inflect; 2027 leading-edge capex re-accelerates bookings.

  $1,300.00 bear — Export-control tightening + capex digestion cut book-to-bill below 0.7.

• AVGOBroadcomcompute

  hold1.83%62
  flow softeningconf

  Funder

  Custom-silicon ASIC leader (~70% share) + VMware software, huge FCF, $7B+ buyback. GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW ASIC contracts; Q2 AI segment +143% to $10.8B, $30B+ bookings.

  Unwind

  AI custom-chip revenue stalls below $25B annual run-rate; hyperscaler in-sourcing at scale.

  Catalyst

  Next earnings — custom-chip run-rate confirmation

  Scenarios · 12mo targets

  $430.00 base

  $520.00 bull — Custom-ASIC pipeline (GOOG/META/Anthropic) drives AI revenue past $30B run-rate.

  $290.00 bear — Hyperscaler in-sourcing + VMware churn stall growth.

• ANETArista Networkscompute

  hold1.57%67
  flow steadyconf

  Funder

  Durable hyperscaler networking franchise, share-gainer since 2004, ~65% GM, net cash, single-image EOS software moat, Ullal capital discipline. Microsoft & Meta named largest customers funding 35% YoY revenue growth; Morgan Stanley OW $190 target.

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; NVDA Spectrum-X displaces Arista at a major hyperscaler.

  Catalyst

  Q2 earnings; hyperscaler concentration + AI-Ethernet share

  Scenarios · 12mo targets

  $190.00 base

  $230.00 bull — AI-cluster Ethernet share gains + 800G ramp sustain 30%+ growth.

  $120.00 bear — Spectrum-X displacement at a hyperscaler + concentration risk.

• FNcompute

  hold1.12%63
  flow softeningconf

  Funder

  Optical transceiver/packaging manufacturer interconnecting hyperscaler AI clusters; capital-light, debt-free. AWS dominant customer drove ~39% YoY growth; record $1.2B Q3 revenue; 800G/1.6T demand from NVDA/AMD GPU clusters.

  Unwind

  Datacom segment sequential decline >5% or gross margin compresses below 11%.

  Catalyst

  Q4 FY26 earnings — Datacom sequential trend

  Scenarios · 12mo targets

  $520.00 base

  $620.00 bull — 1.6T transceiver ramp + AWS/NVDA volumes drive record revenue.

  $360.00 bear — Datacom deceleration + margin compression on customer concentration.

• CCJCamecoenergy

  hold9.95%65
  flow steadyconf

  Funder

  Tier-1 Saskatchewan uranium franchise + Westinghouse 49% JV with Brookfield; tail-risk commodity hedge. DOE $17.5B AP1000 loan commitment, Kazatomprom 8Mlb output cut sustaining deficit, contract book $60+/lb vs ~$93 term; AI-datacenter nuclear power demand.

  Unwind

  Uranium term price collapse below contract floor; reactor-build cancellations; Westinghouse JV impairment.

  Catalyst

  Uranium term-price prints; Westinghouse JV earnings; reactor-build news

  Scenarios · 12mo targets

  $105.00 base

  $130.00 bull — Uranium term price re-rates on reactor buildout; Westinghouse JV earnings inflect.

  $65.00 bear — Uranium price pullback + reactor-build delays.

• GEVGE Vernovaenergy

  hold8.90%63
  flow acceleratingconf

  Funder

  Gas-turbine + grid franchise with pricing power — ~$163B backlog (71% YoY growth), 100GW turbine backlog, 10-20% price realization. Norway GPFG added post-spin; Chevron 4GW behind-the-meter JV + Musk/xAI gas bet; Oracle/Alphabet capex pull-through.

  Unwind

  Wind-segment losses widen materially; backlog cancellations; AI-power gas-turbine order slowdown.

  Catalyst

  Q2 earnings — wind-segment losses + backlog growth

  Scenarios · 12mo targets

  $1,200.00 base

  $1,450.00 bull — Gas-turbine backlog to ~$200B + AI-power PPAs lift margins.

  $780.00 bear — Wind losses widen + AI-power order slowdown.

• SCCOSouthern Copperenergy

  hold9.21%63
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost copper producer, vast reserves, 59.8% GM, large dividend. Copper supply deficit ~320k tonnes 2026, record Q1 NI $1.58B, AI/data-center ~30% of new copper demand by 2030 (BNEF); Mexican-gov ownership backstop.

  Unwind

  Copper price collapse; global recession cutting industrial demand; major mine nationalization risk.

  Catalyst

  Copper price action; Q2 earnings

  Scenarios · 12mo targets

  $195.00 base

  $235.00 bull — Copper deficit widens on AI grid/EV demand; prices break higher.

  $135.00 bear — Recession cuts industrial copper demand; price reversion.

• MPMP Materialsenergy

  hold5.31%
  flow softeningconf

  Funder

  Only scaled US rare-earth + magnet producer; DoD-backstopped moat vs China's 98% magnet control — $400M preferred + $150M loan + 10-yr $110/kg NdPr price floor + 10-yr magnet offtake for the 10X facility. Government price floor caps economic downside.

  Unwind

  DoD price-floor/offtake repealed; magnet-facility ramp fails; China blacklist expands to block all processing-tech access with no offset.

  Catalyst

  Quantification of China blacklist operational impact; magnet-facility ramp updates

  Scenarios · 12mo targets

  $52.00 base

  $75.00 bull — Magnet facility ramps on schedule; DoD/Apple offtake scales US supply.

  $30.00 bear — China blacklist blocks processing tech; magnet ramp slips, FCF stays negative.

• NEMNewmont Corporationenergy

  hold6.43%89
  flow acceleratingconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer, tier-1 long-life assets, strong post-Newcrest FCF, $3.2B net cash Q1. Central-bank gold accumulation; stagflation hedge; TD Cowen upgrade (hold->buy, Jul 14) on valuation.

  Unwind

  Sustained cost overruns / FCF disappointment; gold price break with central-bank buying reversing.

  Catalyst

  Q2 earnings — cost discipline + FCF; gold price / central-bank buying

  Scenarios · 12mo targets

  $105.00 base

  $130.00 bull — Central-bank gold buying + stagflation hedge drive gold higher; FCF/dividend grow.

  $72.00 bear — Gold breaks lower + cost overruns pressure FCF.

• KTOSKratos Defensedefense

  hold10.77%
  flow steadyconf

  Funder

  DoD MACH-TB 2.0 IDIQ prime ($1.45B ceiling, 5-yr); Project Helios $68.3M hypersonic materials; USMC XQ-58A Valkyrie mods; SpaceX/OpenSpace ground-system growth. ARK buying + UK £5B drone investment; backlog >$2B (72% funded).

  Unwind

  Backlog conversion stalls; margin inflection fails to confirm; DoD drone/hypersonic funding cut.

  Catalyst

  USAF/Navy contract awards; margin inflection in next earnings

  Scenarios · 12mo targets

  $55.00 base

  $70.00 bull — Drone/hypersonic contracts convert; margin inflection confirms scale.

  $34.00 bear — Backlog conversion stalls; margins stay thin; peace-deal demand fade.

• HEIHEICOdefense

  hold9.98%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR, disciplined serial acquirer ($1B+/yr). Q2 net income +49% YoY, record sales $1.375B; NDAA mandatory funding + commercial-aerospace MRO.

  Unwind

  Organic growth decelerates below 6% with margin compression; acquisition tape dries up; forward multiple contracts on a growth miss.

  Catalyst

  Next quarterly earnings — organic growth + acquisition cadence

  Scenarios · 12mo targets

  $390.00 base

  $460.00 bull — Acquisition tape + MRO demand sustain 20% FCF CAGR compounding.

  $270.00 bear — Organic growth decelerates + 54x multiple contracts.

• PSNdefense

  hold3.48%50
  flow reversingconf

  Funder

  C5ISR/cyber government-services prime — MDA SHIELD $151B-ceiling IDIQ, DTRA cyber $137M, USAF MATOC $15B, Navy WEXMAC $10B prime awards; recent Qatar Lusail + Blatnik Bridge wins. Defense/infrastructure spending surge.

  Unwind

  Book-to-bill falls below 1.0 two consecutive quarters; confidential-contract revenue softness persists; SHIELD task-order conversion fails. Score 50 (broken) — queued for close at next full deep run; out of scope this patch.

  Catalyst

  Book-to-bill print; SHIELD task-order awards (broken thesis, close pending next deep run)

  Scenarios · 12mo targets

  $62.00 base

  $78.00 bull — SHIELD task orders convert; book-to-bill recovers above 1.0.

  $45.00 bear — Confidential-contract softness persists; backlog conversion fails.

• LLYEli Lillybiology

  hold4.66%70
  flow steadyconf

  Funder

  Premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise (~60% US share, $12B+ quarterly) + oral orforglipron (Foundayo, FDA-approved Apr 2026) + retatrutide Ph3 (~70lb loss); 82.9% GM, FCF+, $27B manufacturing expansion; AtaiBeckley neuroscience add.

  Unwind

  Tirzepatide US script share falls >5pts to NVO over two quarters; GLP-1 pricing/reimbursement shock; pipeline setback.

  Catalyst

  Retatrutide Ph3 readouts; US GLP-1 script-share data vs NVO

  Scenarios · 12mo targets

  $1,350.00 base

  $1,650.00 bull — Orforglipron oral + retatrutide extend GLP-1 dominance; obesity TAM expands.

  $950.00 bear — NVO share recovery + reimbursement pressure compress GLP-1 economics.

• VRTXVertex Pharmaceuticalsbiology

  hold3.12%76
  flow acceleratingconf

  Funder

  Durable biology compounder — CF monopoly (Trikafta) cash engine, self-funded, 86.8% GM, fortress balance sheet, $3.71B TTM FCF. Casgevy commercializing across 12+ jurisdictions (Medicare Cell & Gene Access Model); $10B Crinetics acquisition diversifies into rare endocrine (acromegaly/CAH). Highest-conviction biology name (76) — building the durable leg to cure the §2/§3 pillar floor.

  Unwind

  CF franchise erodes faster than non-CF revenue can replace; Crinetics integration destroys value; Journavx/Casgevy launches stall.

  Catalyst

  Crinetics deal close/integration; Casgevy uptake; Journavx (suzetrigine) launch

  Scenarios · 12mo targets

  $560.00 base

  $680.00 bull — Casgevy + Journavx scale, Crinetics accretive; CF cash engine funds diversification.

  $410.00 bear — CF erosion outpaces new franchises; Crinetics premium destroys value.

• ARGXargenxbiology

  hold2.22%70
  flow acceleratingconf

  Funder

  argenx — Vyvgart/Vyvgart Hytrulo (efgartigimod) autoimmune franchise; self-funded commercial-stage biotech, high-margin, net cash, durable FcRn franchise. FDA all-serotype gMG expansion (18% TAM), Sanofi CIDP competitor failure strengthens the moat, myositis/Sjogren's pipeline; $6B->$16B gMG TAM by 2036.

  Unwind

  FcRn class competition erodes Vyvgart share; CIDP/myositis label expansions fail; commercial ramp decelerates.

  Catalyst

  CIDP/myositis/SjD label decisions; Vyvgart quarterly sales

  Scenarios · 12mo targets

  $1,000.00 base

  $1,200.00 bull — Vyvgart label expansions (CIDP/myositis/SjD) + FcRn leadership drive $16B TAM capture.

  $680.00 bear — FcRn competition erodes share; pipeline label expansions miss.

Warnings

• stale_policy guard: VRTX add → hold (delta zeroed)
• tilt_truncated: energy tilt +5pp truncated at 40% cap
• §2 cap re-applied after pillar tilt: MU
• §2 cap re-applied after pillar tilt: NVDA
• §2 cap re-applied after pillar tilt: AVGO
• §2 cap re-applied after pillar tilt: ANET
• §2 cap re-applied after pillar tilt: FN
• §2 cap re-applied after pillar tilt: GEV
• §2 cap re-applied after pillar tilt: MP
• §2 cap re-applied after pillar tilt: NEM
• §2 cap re-applied after pillar tilt: KTOS
• §2 cap re-applied after pillar tilt: HEI
• §2 cap re-applied after pillar tilt: PSN
• §2 cap re-applied after pillar tilt: LLY
• §2 cap re-applied after pillar tilt: VRTX
• cash_reconcile: executed cash 0.91% below the 8.29% SGOV reserve — sold 4.12pp of over-deployment back to cash across LLY (§5.4/§10.6)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.